Alpha Cognition Inc. (Nasdaq: ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative ...
Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and ...
A 2026 informational consumer research report examining FocusMax cognitive support marketing claims, ingredient-level research context, proprietary blend transparency, pricing disclosures, and verific ...
Memopezil is at the center of a rapidly growing conversation about cognitive health in 2026, as consumer interest in brain support has reached an all-time high, with search volume for terms like ...
The Adapt Oculus trial is unique in that it includes a patient population often overlooked in clinical trials, patients ...
X recently announced results from additional analyses of its blockbuster FcRn inhibitor Vyvgart in the phase III Adapt Oculus study. The study evaluated the efficacy and safety of Vyvgart administered ...
VANCOUVER, British Columbia & GRAPEVINE, Texas, February 25, 2026--Alpha Cognition Inc. (NASDAQ: ACOG) ("Alpha Cognition," "ACI," or the "Company"), a clinical-stage biopharmaceutical company ...
As of December 2024, five Food and Drug Administration (FDA)-approved therapies can treat myasthenia gravis symptoms and may allow partial to complete remission. There is still no cure, but modern ...
ABSTRACT: The present paper is part of publication of the proceedings of the international symposium “Tropical Islands and Biodiversity”. The aim is to place emphasis on natural products from plant ...
VANCOUVER, British Columbia & DALLAS--(BUSINESS WIRE)--Alpha Cognition Inc. (Nasdaq: ACOG), a commercial-stage biopharmaceutical company developing therapies for neurodegenerative diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results